Fentanyl 12 Mcg Transdermal Patch For Postoperative Pain
The Effect Of Fentanyl 12 Mcg Transdermal Patch On Postoperative Pain Following Unilateral, Single-Level Laminectomy/Discectomy: A Randomized, Controlled, Double-Blind Study
1 other identifier
interventional
78
0 countries
N/A
Brief Summary
The investigators designed a prospective randomized study to investigate the effect of fentanyl 12 mcg transdermal patch on postoperative pain following unilateral, single-level laminectomy/discectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4 postoperative-pain
Started Mar 2015
Typical duration for phase_4 postoperative-pain
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedFirst Submitted
Initial submission to the registry
June 23, 2017
CompletedFirst Posted
Study publicly available on registry
June 26, 2017
CompletedJune 26, 2017
June 1, 2017
1.5 years
June 23, 2017
June 23, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Numeric rating score for pain (NRS)
Postoperative 24 hours
Study Arms (2)
Fentanyl Group
ACTIVE COMPARATORPatients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
Control group
NO INTERVENTIONInterventions
Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
Eligibility Criteria
You may qualify if:
- Patients between the ages of 20-70 years
- ASA physical status 1-2 patients undergoing single-level laminectomy/discectomy
You may not qualify if:
- A history of allergy to any study drugs
- History of opioid use, obstructive sleep apnea
- Any psychological disorders
- hepatic or renal failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor
Study Record Dates
First Submitted
June 23, 2017
First Posted
June 26, 2017
Study Start
March 1, 2015
Primary Completion
September 1, 2016
Study Completion
December 1, 2016
Last Updated
June 26, 2017
Record last verified: 2017-06